SGMOQ — Sangamo Therapeutics Share News
0.000.00%
Last trade - 00:00- $18.64m
- -$8.94m
- $39.55m
Sangamo Q4 revenue misses analyst expectations
Brief: Sangamo Therapeutics Q4 EPS USD -0.11
U.S. STOCKS ON THE MOVE-Allurion, Rithm Capital, Medtronic
U.S. STOCKS ON THE MOVE-Western Digital, Broadridge, WTW
Sangamo Therapeutics slides after $25 million stock sale
Brief: Sangamo Therapeutics Inc - On Feb 2, Prathyusha Duraibabu Terminated As Principal Financial Officer - SEC Filing
Brief: Sangamo Therapeutics Initiates Rolling Submission Of BLA To U.S. FDA
U.S. STOCKS ON THE MOVE-CrowdStrike Holdings, Procter & Gamble, Ford Motor
U.S. STOCKS ON THE MOVE-Bristol Myers Squibb, Cloudflare, Boeing
Sangamo jumps as US FDA fast-tracks drug for chronic nerve pain
Brief: Sangamo Therapeutics Receives U.S. FDA Fast Track Designation For ST-503
Brief: Sangamo Therapeutics Announces FDA Acceptance Of BLA Rolling Submission Request
Sangamo Therapeutics Q3 revenue falls short, net loss widens
Brief: Sangamo Therapeutics Appoints Nikunj Jain As Principal Accounting Officer - SEC Filing
Brief: Sangamo Therapeutics CFO Prathyusha Duraibabu Resigned - SEC Filing
Sangamo Therapeutics Inc reports results for the quarter ended June 30 - Earnings Summary
Brief: Sangamo Therapeutics Q2 EPS USD -0.08 Vs. IBES Estimate USD -0.13
Sangamo Therapeutics Inc expected to post a loss of 13 cents a share - Earnings Preview
Sangamo Therapeutics Inc expected to post a loss of 13 cents a share - Earnings Preview